Biden administration to defend mandates against legal challenges; Regeneron antibodies reduce COVID risk by 82%; EU to provide recommendations for Merck’s antiviral COVID pill.
Kaiser survey shows vaccine equity messaging getting lost
Pfizer’s antiviral COVID-19 pill cuts risk of hospitalization and death by 89%, per study; Bluebird Bio signs lease for new HQ; Texas AG challenges federal vax mandate.
Five things for health marketers to know: Friday, November 5, 2021
OSHA gives businesses until Jan. 4 to comply with vaccine mandates; BMS and Gilead CAR-T cell therapies show efficacy; Moderna drops chikungunya virus mRNA program.
Five things for health marketers to know: Thursday, November 4, 2021
Ford implements vaccine mandate for salaried employees; Clade Therapeutics snares $87 million in Series A funding; CDC approves Pfizer vax for 5- to 11-year-olds.
Five things for health marketers to know: Wednesday, November 3, 2021
FDA reviews Moderna vaccine’s link to heart problems; Merck to co-develop new cytokine therapies; physician advocates of Biogen’s Aduhelm have financial ties to company.
Five things for health marketers to know: Monday, November 1, 2021
Speaker Pelosi’s office works on last-ditch drug pricing effort; Moderna to supply 56.5 million more COVID-19 doses to countries in need; AbbVie plans to submit psychiatric drug cariprazine for approval despite failed Phase III studies
Could a cheap drug spell ‘game over’ for the pandemic?
Prescribing patterns are set to change as recent studies with fluvoxamine, a widely available antidepressant, show significantly reduced COVID-19 hospitalization rates.